Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Octreotide for the treatment of sulfonylurea poisoning.

Glatstein M, Scolnik D, Bentur Y.

Clin Toxicol (Phila). 2012 Nov;50(9):795-804. doi: 10.3109/15563650.2012.734626. Epub 2012 Oct 10. Review.

PMID:
23046209
2.

Octreotide's role in the management of sulfonylurea-induced hypoglycemia.

Dougherty PP, Klein-Schwartz W.

J Med Toxicol. 2010 Jun;6(2):199-206. doi: 10.1007/s13181-010-0064-z. Review.

3.

Octreotide for sulfonylurea-induced hypoglycemia following overdose.

Carr R, Zed PJ.

Ann Pharmacother. 2002 Nov;36(11):1727-32. Review.

PMID:
12398568
4.

Treatment of sulfonylurea and insulin overdose.

Klein-Schwartz W, Stassinos GL, Isbister GK.

Br J Clin Pharmacol. 2016 Mar;81(3):496-504. doi: 10.1111/bcp.12822. Epub 2016 Jan 6. Review.

5.

High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning.

Engebretsen KM, Kaczmarek KM, Morgan J, Holger JS.

Clin Toxicol (Phila). 2011 Apr;49(4):277-83. doi: 10.3109/15563650.2011.582471. Review.

PMID:
21563902
6.
7.

Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide.

Lheureux PE, Zahir S, Penaloza A, Gris M.

Crit Care. 2005;9(6):543-9. Epub 2005 Sep 7. Review.

8.

Are one or two dangerous? Sulfonylurea exposure in toddlers.

Little GL, Boniface KS.

J Emerg Med. 2005 Apr;28(3):305-10. Review.

PMID:
15769574
9.

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

Iltz JL, Baker DE, Setter SM, Keith Campbell R.

Clin Ther. 2006 May;28(5):652-65. Review.

PMID:
16861088
10.

Insulin glargine: a systematic review of a long-acting insulin analogue.

Wang F, Carabino JM, Vergara CM.

Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. Review.

PMID:
12860485
11.

Hypoglycemia following inadvertent and factitious sulfonylurea overdosages.

Klonoff DC, Barrett BJ, Nolte MS, Cohen RM, Wyderski R.

Diabetes Care. 1995 Apr;18(4):563-7. Review.

PMID:
7497872
12.

Velaglucerase alfa for the management of type 1 Gaucher disease.

Morris JL.

Clin Ther. 2012 Feb;34(2):259-71. doi: 10.1016/j.clinthera.2011.12.017. Epub 2012 Jan 20. Review.

PMID:
22264444
13.

Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.

Seymour N, Sawh SC.

Can J Anaesth. 2013 May;60(5):492-9. doi: 10.1007/s12630-012-9879-1. Epub 2013 Jan 18. Review.

PMID:
23328959
14.

Octreotide in hyperinsulinism.

Barrons RW.

Ann Pharmacother. 1997 Feb;31(2):239-41. Review.

PMID:
9034427
15.

Review of linagliptin for the treatment of type 2 diabetes mellitus.

Neumiller JJ, Setter SM.

Clin Ther. 2012 May;34(5):993-1005. doi: 10.1016/j.clinthera.2012.02.029. Epub 2012 Mar 21. Review.

PMID:
22440191
16.

High-dose insulin therapy for calcium-channel blocker overdose.

Shepherd G, Klein-Schwartz W.

Ann Pharmacother. 2005 May;39(5):923-30. Epub 2005 Apr 5. Review.

PMID:
15811898
17.

Sulfonylureas. Why, which, and how?

Melander A, Lebovitz HE, Faber OK.

Diabetes Care. 1990 Aug;13 Suppl 3:18-25. Review.

PMID:
2209339
18.

Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.

Harrigan RA, Nathan MS, Beattie P.

Ann Emerg Med. 2001 Jul;38(1):68-78. Review.

PMID:
11423816
19.
20.

Use of sulfonylurea agents in older diabetic patients.

Peters AL, Davidson MB.

Clin Geriatr Med. 1990 Nov;6(4):903-21. Review.

PMID:
2224754

Supplemental Content

Support Center